Navigation Links
InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
Date:5/28/2009

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT.

Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Purposefully designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby allowing the retention of the clinically proven anti-diabetic efficacy of PPAR gamma activation, while mitigating or eliminating the well recognized side effects of TZD full PPAR gamma agonists rosiglitazone and pioglitazone (Avandia(R) and Actos(R) respectively).

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
4. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
5. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
10. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
11. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 2017 , ... ProRehab Physical Therapy (PRPT) is ... therapy provider for Derby City CrossFit, effective immediately. , In addition to treating ... effectively as possible, ProRehab’s sports physical therapists will work with athletes to maximize ...
(Date:4/25/2017)... ... 2017 , ... A recent report from the Wisconsin Institute ... 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools participating ... student test score performance, the report’s limited analyses fail to provide answers as ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of ... I focus on preventative care with all my patients to alleviate possible future issues. I ... free to contact my office and my trained staff will assist you in any way ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
Breaking Medicine News(10 mins):